In addition, several studies demonstrated that another SCFA butyrate was able to attenuate NAFLD by regulating gut microbiota, intestinal tight junctions, hepatic Glucagon-like peptide-1 (GLP-1) receptor expression, and TLR4 pathways [35,36,37,38]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.